@UChicagoMed Comprehensive Cancer Center designated by @theNCI for 50+ yrs. #NothingWillStopUs #WeAreNCIDesignated uchicagocancer.bsky.social
Chicago, IL
- Tweets 15,215
- Following 1,590
- Followers 10,187
- Likes 9,254
A phase 1 trial led by Michael Bishop, MD, at @UChicagoMed and investigators at @MassGenBrigham found that investigational BCMA-targeted CAR-T therapy anito-cel produced deep, durable responses in relapsed/refractory multiple myeloma. #mmsm
ow.ly/agH950ZRalu
1
3
9
463
In a phase 1 study of anito-cel, a CAR T-cell therapy, for relapsed or refractory myeloma, all 38 patients had a response. Severe cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome were rare. Full study results: nej.md/4ArvK6r
Science behind the Study: Anito-cel for Multiple Myeloma nej.md/4hF5Gxj
ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Phase 1 Study of Anito-cel, a D-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma." The graph shows progression-free survival among all patients who received anito-cel. The NEJM identity sits at the bottom.
3
52
115
33,466
Meet Fay Hlubocky, PhD, a clinical health psychologist and ethicist with expertise in psychosocial oncology. Follow her for information about physician burnout and well-being, and how financial toxicity affects cancer patients. #FollowFriday @FayUCCancerCr @UChicagoHemOnc
1
5
275
A phase 1 trial led by Michael Bishop, MD, at @UChicagoMed and investigators at @MassGenBrigham, found that investigational BCMA-targeted CAR-T therapy anito-cel produced deep, durable responses in relapsed/refractory multiple myeloma. @mrbishop_UC_BMT
ow.ly/agH950ZRalu
3
4
7
501
UChicago Medicine Comprehensive Cancer Center retweeted
check out the @NCCN webinar on MPNs featuring @Anand_88_Patel and RN Navigator Jack Reilly as panelists!
nccn.org/patientresources/pa…
3
8
299
🔥Hot off the press: Michael Bishop, MD, and colleagues report results from the phase 1 study of anito-cel, a BCMA-directed CAR T-cell therapy, showing encouraging activity in heavily pretreated relapsed/refractory multiple myeloma. @NEJM @mrbishop_UC_BMT
ow.ly/itRY50ZR8qu
1
2
14
654
In a recent @SurvivorNetTeam feature, Dr. Akash Patnaik, MD, PhD, highlights growing momentum in precision-based targeted therapies, immune-based approaches, and radioligand treatments such as FPI-2265 for advanced prostate cancer. @AkashPatnaik7
ow.ly/vnZO50ZR6Yq
4
7
314
On this #WorldCancerResearchDay, together with researchers, clinicians, patients, and partners, we remain committed to advancing knowledge, accelerating innovation, and improving cancer outcomes for all. #AdvancingCancerResearchTogether
@UChicagoMed
ow.ly/4bq150ZQQaq
4
4
179
UChicago Medicine Comprehensive Cancer Center retweeted
It has been a real delight to have had @UCCancerCenter be a part of the anito-cel journey. Now we await the results of the phase 2 and the PDUFA date - December 23!
In a phase 1 study of anito-cel, a CAR T-cell therapy, for relapsed or refractory myeloma, all 38 patients had a response. Severe cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome were rare. Full study results: nej.md/4ArvK6r
Science behind the Study: Anito-cel for Multiple Myeloma nej.md/4hF5Gxj
ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Phase 1 Study of Anito-cel, a D-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma." The graph shows progression-free survival among all patients who received anito-cel. The NEJM identity sits at the bottom.
3
3
27
3,168
At a recent US Prostate Cancer Consensus Conference, Drs. Russell Szmulewitz and Rahul Aggarwal shared insights on the use of PARP inhibitor beyond BRCA2, and how to balance efficacy with long-term toxicity. @UChicagoMed @UCSF
Watch the interview here: ow.ly/PNUp50ZQJZA
4
5
366
How Do I Know if a Clinical Trial Is Right for Me? A comic explaining the risks and benefits of participating in a cancer clinical trial, translated for a Mandarin-speaking audience.
2
5
298
Join us for the 5th annual #SouthSideScienceFestival, a free community event featuring 100+ interactive demos. Stop by "Cancer Corner" for watercolor pipette painting, Coco the giant inflatable colon, DNA with Legos, and bike-generated smoothies.
RSVP: ms.spr.ly/6175abR5D
2
232
In a new study published in @MolecularCell, Chuan He, PhD, and colleagues reveal that 5-azaC, a drug used to treat blood cancers, works through a previously underappreciated mechanism involving RNA methylation rather than just DNA effects. @UChiChemistry
ow.ly/P0Lg50ZPMq2
2
11
51
3,847
UChicago Medicine Comprehensive Cancer Center retweeted
Stay up to date on recent @US_FDA approvals for cancer prevention, diagnosis, and treatment therapeutics, as well as other products. Learn about the recent progress against cancer: brnw.ch/21x5PID
3
2
509
RT @marinagarassino: Proud to co-chair Innovation and Technology in the @TheLancet commission for lung cancer. Amazing meeting with an inc…
1
8
Meet Barbara L. Kee, PhD, a scientist studying the molecular mechanisms that control immune cell development and function and how they contribute to cancer and autoimmune diseases. ow.ly/Zzbt50ZvbYI #FollowFriday @UChicagoImmuno @UChicagoCCB @UChicagoPath
4
13
549
UChicago Medicine Comprehensive Cancer Center retweeted
September is Childhood Cancer Awareness Month — a time to honor the strength of our pediatric patients and the importance of lifelong support.
Read about the Childhood Cancer Survivors Center at UChicago Medicine Comer Children's Hospital: uchicagomedicine.org/forefro…
ALT Photo of two people smiling in an embrace.\nHeadline: Life after childhood cancer: UChicago Medicine center offers care into adulthood\nUChicago Medicine Comer Children's
2
53
🔥Hot off the press: A new study in @Cancer_Cell from Dr. Weichselbaum (@rweichselbaum) and colleagues show how high-dose radiation increases TET2 expression, activating immunosuppressive MDSCs to drive tumor progression. @UChicagoRadonc @UChicagoMed
ow.ly/zj6J50ZOR6z
5
12
40
2,692
We were thrilled to host Curt Pesman, author of the book "SuperSurvivors Stage 5" for a fireside chat with fellow cancer survivor and patient advocate Wenora Johnson. Curt is starting a movement to recognize the thousands of advanced cancer patients who are living 10 yrs or more.
5
307
September marks #ChildhoodCancerAwarenessMonth!
At @ComerChildrens, cancer care goes beyond diagnosis and treatment. The @UChicagoMed Childhood Cancer Survivors Center helps prevent, and treat long-term issues associated with cancer therapy. #SurvivorCare
ow.ly/geK850ZOQ3c
1
4
301